FY2026 · ended May 31, 2026 · Revenue $870.40M, -2.7% YoY · Filed Jul 30, 2026
Neogen Corporation (NEOG) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In fiscal 2026, which ended May 31, 2026, it reported revenue of $870.4 million and a net loss of $7.9 million. Free cash flow was $31.9 million. As of Aug 31, 2026 it held $172.0 million in cash and investments and $774.2 million in total debt.
Revenue (TTM)
$884.00M
Net income (TTM)
$-56.10M
Operating cash flow (TTM)
$85.30M
Free cash flow (TTM)
$49.80M
EPS (TTM)
$-0.26
Dividend per share
None
Shares outstanding
218.06M
+0.4% vs prior year
Net cash
$-602.20M
as of Aug 31, 2026
Operating margin
-0.8%
FY 2027
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- NEOG (Nasdaq)
- Fiscal year ends
- May 31
- Incorporated in
- MI
- Headquarters
- Lansing, MI
- SEC filer status
- Large accelerated filer
- SEC CIK
- 711377
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 May 31, 2026 |
FY 2025 May 31, 2025 |
FY 2024 May 31, 2024 |
FY 2023 May 31, 2023 |
FY 2022 May 31, 2022 |
|---|---|---|---|---|---|
| Revenue | $870.4M | $894.7M | $924.2M | $822.4M | $527.2M |
| Operating income | -$21.6M | -$1.1B | $58.6M | $37.5M | $58.6M |
| Net income | -$7.9M | -$1.1B | -$9.4M | -$22.9M | $48.3M |
| Diluted EPS | -$0.04 | -$5.03 | -$0.04 | -$0.12 | $0.45 |
| Operating cash flow | $83.2M | $58.2M | $35.3M | $41.0M | $68.0M |
| Free cash flow | $31.9M | -$46.4M | -$76.1M | -$24.7M | $43.6M |
| Total assets | $3.3B | $3.4B | $4.5B | $4.6B | $992.9M |
| Total liabilities | $1.3B | $1.4B | $1.4B | $1.4B | $105.6M |
| Stockholders' equity | $2.1B | $2.1B | $3.1B | $3.1B | $887.4M |
| Cash and investments | $185.5M | $129.0M | $170.9M | $245.6M | $381.1M |
| Total debt | $812.7M | $915.0M | $908.7M | $897.5M | $3.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Oct 26, 2026 | Oct 1, 2026 |
| 10-Q | Quarterly report | Oct 7, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 7, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 6, 2026 | Oct 6, 2026 |
| ARS | Annual report to shareholders | Aug 21, 2026 | May 31, 2026 |
All 1004 Neogen Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.